Shots:

• The P-III (HERCULES) trial is assessing tolebrutinib vs PBO for nrSPMS. Study showed 31% delay in time to onset of 6mos. CDP and 10% vs 5% of them experienced confirmed disability improvement. Data was highlighted at ECTRIMS 2024
• The company further presented results of P-III (GEMINI 1 & 2) studies of tolebrutinib vs Aubagio (SoC) for RMS. Both the trials did not meet their 1EPs of improved ARR; a pooled analysis revealed tolebrutinib delayed 6mos. CDW by 29%; ARR was 0.13 vs 0.12 (GEMINI 1) as well as 0.11 (GEMINI 2) & 0.12 (pooled analysis) with both
• In addition, regulatory submissions worldwide are planned during H2’24, with results from the P-III (PERSEUS) study in primary progressive MS during H2’25

Ref: Sanofi | Image: Sanofi

Related News: Sanofi Releases P-III (HERCULES) Data of Tolebrutinib (BTKi) for non-relapsing Secondary Progressive MS (nrSPMS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com